Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEP-28122 |
Synonyms | |
Therapy Description |
CEP-28122 is a small molecule inhibitor of ALK that inhibits growth of ALK-positive tumors (PMID: 22203728). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEP-28122 | ALK Inhibitor 33 | CEP-28122 is a small molecule inhibitor of ALK that inhibits growth of ALK-positive tumors (PMID: 22203728). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK negative | lung non-small cell carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728). | 22203728 |
ALK R1275Q | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728). | 22203728 |
EML4 - ALK | lung non-small cell carcinoma | sensitive | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-28122 inhibited growth of non-small cell lung carcinoma cell lines harboring EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 22203728). | 22203728 |
ALK F1174L | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture (PMID: 22203728). | 22203728 |
ALK negative | colon carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728). | 22203728 |
ALK amp | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of ALK-amplified neuroblastoma cells in culture (PMID: 22203728). | 22203728 |
ALK negative | leukemia | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728). | 22203728 |
ALK negative | lymphoma | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728). | 22203728 |
ALK wild-type | neuroblastoma | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 22203728). | 22203728 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|